Search or ask a question

Is there risk for infection?

Chimeric antigen receptor

Cytokine release syndrome

Chimeric Antigen Receptor T-Cell Therapy

Nosocomial infection control

Best insight from top research papers

There is a risk for infection in various contexts. In the context of CAR T-cell therapy for B-cell malignancies, the risk of infection is increased due to factors such as immunosuppression, lymphodepleting chemotherapy, and complications like cytokine release syndrome . In the context of hospital hygiene and infection control, the occurrence of hospital-acquired infections can be reduced by implementing infection control measures, but achieving a zero infection rate in sterile operative procedures is not achievable . However, in the context of reusable waste containers, the risk of pathogen or disease transfer is negligible to nil, and disinfection and microbiological monitoring are not indicated . In the context of liver transplantation in children, there are various risk factors for bacterial, viral, and fungal infections, including immunosuppressive switch, re-LT, and cytomegalovirus infection . Finally, in the context of the ongoing COVID-19 pandemic, there is a high risk of infection in onsite workplaces, and a proposed Covid-19-safe workplace platform aims to monitor and minimize infection risks .

Answers from top 3 papers

PDF

Open Access

More filters

Papers (3)	Insight
Open access•Journal Article•DOI Infection Risk in Sterile Operative Procedures. Evelina Tacconelli, Niklas F. Müller, Sebastian Lemmen, Nico T. Mutters, Stefan Hagel, Elisabeth Meyer - Show less +5 more 22 Apr 2016-Deutsches Arzteblatt International 7 Citations	Yes, there is a risk for infection in sterile operative procedures, but the extent of the risk varies depending on multiple factors.
Journal Article•DOI Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Carlota Gudiol, Russell E. Lewis, Paolo Strati, Dimitrios P. Kontoyiannis - Show less +3 more 15 Jan 2021-The Lancet Haematology 34 Citations	Yes, there is a risk for infection associated with chimeric antigen receptor T-cell therapy due to factors such as immunosuppression and administration of lymphodepleting chemotherapy.
Open access•Journal Article•DOI Using reusable containers for hospital waste: is there an infection risk? Terry Richard Grimmond 01 Jan 2013-The Southern African Journal of Epidemiology and infection 2 Citations	No, the literature confirms that there is negligible to nil risk of pathogen or disease transfer with reusable waste containers.

My columns

Related Questions

What is the risk that a dental periapical infection spreads to other parts of the body?4 answersDental periapical infections have the potential to spread to other parts of the body, causing extraoral infections in tissues and organs. These infections can be serious and even life-threatening, such as cardiovascular infections and brain abscesses. Prompt assessment and referral to a tertiary hospital is necessary for cases at risk of airway compromise. General medical practitioners and non-specialists should be aware of the initial diagnosis and management of acute dental infections. Risk factors for the spread of dental infections include smoking, male gender, excessive alcohol use, and irregular dental care. Microorganisms in the oral cavity can cause systemic diseases through the bloodstream, with potential complications including brain abscess, meningitis, and lung or liver abscess. Prevention is crucial in reducing the risk of these infections.

What are the risk factors for burn infections?4 answersBurn infections have several risk factors. Poor hand hygiene and lack of adherence to wearing Personal Protective Equipment (PPE) and contact isolation precautions were identified as significant contributing factors to acquiring infections. Burn patients are at high risk of infections due to severe impairment of immunity and loss of skin barrier function. The history of antibiotic usage, length of ICU stay, mechanical ventilation, and catheter usage were found to be important risk factors for infections associated with antibiotic-resistant Gram-negative bacilli. Multiple factors increase burn patients' risk of invasive infection and sepsis, including underlying factors and co-morbidities, the percent total body surface area of the burn, delays in burn wound excision, and microbial virulence/bacterial count. Risk factors associated with time to first healthcare-associated infection (HAI) in burn patients include burn size (TBSA > 20%), burn mechanism (flames and scalds), central venous catheter use, and mestizo race.

What are the risk factors for pyogenic infections?5 answersPyogenic infections have various risk factors. In one study, high levels of patient colonization, contamination of the environment by nosocomial strains of microorganisms, and the degree of participation of mother's relatives in delivery were identified as risk factors for pyogenic and septic infections in mothers and newborns. Another study found that the most prevalent pathogens causing pyogenic wound infections were Staphylococcus aureus and Klebsiella species, and there was a high level of drug resistance among both Gram-positive and Gram-negative bacteria. Additionally, the emergence of antimicrobial drug resistance due to the injudicious use of antibiotics has made the treatment of wound infections challenging, with Methicillin Resistant Staphylococcus Aureus (MRSA) and Inducible Clindamycin Resistance (ICR) being common. Patients with rheumatoid arthritis are also at risk of severe pyogenic infections, particularly caused by Staphylococcus aureus.

What are the risks?5 answersThe risks associated with the topics covered in the abstracts include: - For the treatment of squamous cervical intraepithelial neoplasia, excision methods such as cone biopsy may lead to long-term pregnancy-related morbidity, incomplete excision, and premature labor. Large loop excision of the transformation zone (LLETZ) appears to have fewer adverse outcomes. - Eating disorders, such as anorexia nervosa (AN) and bulimia nervosa (BN), have a chronic and relapsing course, high rates of psychiatric comorbidity, and increased mortality risk. Risk factors for the development of eating disorders include female gender, early feeding or undereating problems, maternal depressive symptoms, higher self-esteem, and higher BMI. - Chickenpox during pregnancy can have complications, fetal or perinatal infection, and mortality, with the severity of the disease influencing the risks. - Switching between different formulations of cyclosporin, an immunosuppressive agent used in renal transplant recipients, may induce adverse drug reactions and acute cellular rejection. The therapeutic equivalency of different formulations is uncertain, and caution should be exercised when switching. - Individuals with a history of atopy are at increased risk of becoming latex allergic. Specific food allergies can also cross-react with latex. Minimizing exposure to latex products and using non-latex alternatives is important to prevent latex allergy.

What are the risk factors for developing an infection associated with health care BLSE?5 answersRisk factors for developing an infection associated with health care include patient characteristics, type of care, and the setting. Specific risk factors identified in the abstracts include damaged skin, mucous membranes, and respiratory pathways as routes of transmission. Other risk factors include age, immune status, underlying disease, and diagnostic procedures such as endoscopy, catheterization, and mechanical ventilation. Diabetes mellitus, immunosuppression, body temperature, surgery time, reoperation, cephalosporin exposure, days of exposure to central venous catheter, intensive care unit (ICU) admission, ICU stay, and mechanical ventilation are also identified as risk factors for health care-associated infections. These risk factors contribute to the development of infections such as surgical site infections, bloodstream infections, urinary tract infections, catheter-associated urinary tract infections, pneumonia, and decubitus ulcer infections.

What factors increase the risk of MRSA?10 answers

See what other people are reading

What is the future of advanced therapy?

The future of advanced therapy appears promising, with a focus on cell and gene therapies, automation in cell manufacturing, and precision medicine. These therapies, based on genes, cells, or tissues, offer innovative treatment opportunities for diseases beyond traditional approaches. Despite challenges like high costs and methodological uncertainties, advanced therapies are expected to dominate the market in the coming decades, requiring reliable health technology assessment programs and financial coverage for their success. Research trends highlight technologies like micromachined electrode arrays and optoelectronic probes for potential future therapies, emphasizing the importance of technological maturity for successful implementation. Overall, advancements in advanced therapies hold great promise for revolutionizing medical treatments and moving towards precision medicine in the near future.What are the benefits of trial transcripts?

Trial transcripts offer various advantages in different contexts. They can enhance precision oncology trials by integrating transcriptomics to predict patient responses to targeted therapies. Additionally, real-world data (RWD) integrated with transcriptomics can provide insights into disease pathways and clinical outcomes, aiding in personalized medicine. Moreover, trial transcripts can improve the accuracy of audio data recognition, facilitating the processing of trial information for multiple terminals. Overall, trial transcripts play a crucial role in advancing medical research, optimizing patient selection for treatments, and improving the efficiency of clinical trials through data integration and analysis.Dose of Camptothecin for treatment of colorectal cancer

The effective dose of a camptothecin derivative for the treatment of colorectal cancer is approximately 0.05 to 1 mg/kg body weight/day when dissolved in a non-aqueous solvent, as suggested in a study focusing on an oral pharmaceutical composition. Camptothecins, including irinotecan, are potent topoisomerase I inhibitors used in colorectal cancer treatment, but their high toxicity and administration challenges have been noted. Research has explored the upregulation of DNA damage response-related molecules and apoptosis proteins by a novel topoisomerase inhibitor, PCC0208037, showing promising anti-tumor efficacy in colorectal cancer cells and xenograft models, potentially offering a comparative advantage over standard treatments like irinotecan. Additionally, combining topoisomerase inhibitors like camptothecin with immune-checkpoint inhibitors has been suggested to enhance treatment outcomes in colon cancer by modulating immunoregulatory responses.How immunocal impact infant cancer?

Immunotherapy has revolutionized pediatric cancer treatment, offering promising outcomes for previously challenging cases. Monoclonal antibodies, bispecific antibodies, and cellular therapies like CAR T-cells and NK cells have shown significant clinical responses in pediatric cancers, including neuroblastoma and leukemia. Immunotherapies have demonstrated impressive antitumor effects in high-risk neuroblastoma and acute B-cell lymphoblastic leukemia, enhancing survival rates. Despite initial disappointments in pediatric sarcomas, ongoing trials suggest that immunotherapy will eventually improve outcomes for high-risk malignancies, broadening the therapeutic arsenal against pediatric cancers. The specificity for cancer cells, in vivo persistence, and potency against refractory diseases make immunotherapies a valuable addition to conventional treatments, potentially reducing the chemotherapeutic burden while increasing cure rates in pediatric cancer.How have tumor-on-a-chip platforms evolved in recent years to facilitate the study of cancer-immune system crosstalk?

Tumor-on-a-chip platforms have evolved significantly in recent years to enhance the study of cancer-immune system crosstalk. These platforms utilize microfluidic technologies to create 3D cell co-cultures that mimic the tumor microenvironment, enabling researchers to investigate immune cell recruitment, tumor progression, and response to immunotherapies in a patient-specific manner. By incorporating various cell types, such as cancer cells, immune cells, and stromal cells, these platforms can replicate the complex interactions within the tumor ecosystem. Additionally, advanced imaging techniques and computational algorithms allow for real-time monitoring of cellular behaviors and responses to treatments. Overall, tumor-on-a-chip platforms offer a promising approach to advancing our understanding of cancer-immune system interactions and improving the efficacy of immunotherapies through personalized medicine applications.What are the Clinical and preclinical states of CAR T cell therapy in vivo for solid tumors cancer?

Clinical and preclinical states of CAR T-cell therapy for solid tumors cancer are evolving. Challenges like antigen heterogeneity and immunosuppressive tumor microenvironment hinder CAR T-cell efficacy in solid tumors. Strategies to enhance CAR T-cell function include incorporating co-stimulatory domains, developing armored CAR-T cells, and exploring other immune cells like CAR-NK and CAR-M cells. Novel CAR T-cell products like YTB323 show enhanced in vivo expansion and antitumor activity in preclinical models, with promising safety and efficacy profiles in clinical trials for r/r DLBCL. To overcome limitations such as restricted trafficking, hypoxic TME, antigen escape, and exhaustion, researchers are advancing CAR designs and combining therapies to optimize clinical efficacy in solid tumors.5)What are the side effects and testing complexities of CAR-T cell therapy in solid tumors ?

CAR-T cell therapy in solid tumors presents challenges such as severe toxic reactions, antigen escape, limited infiltration, and immunosuppression. The therapy's side effects include cytokine release syndrome, neurotoxicity, and on-target off-tumor toxicities due to the difficulty in identifying unique tumor antigen targets. Testing complexities arise from the hostile tumor microenvironment, which hinders CAR-T cell survival and function. Strategies like dual-targets, receptor system switches, and engineered CARs to shield inhibitory signaling molecules are being explored to enhance specificity, minimize toxicities, and improve CAR-T cell function in solid tumors. Combining CAR-T cell therapy with radiotherapy has shown promise in enhancing immunity, promoting infiltration, and improving the tumor microenvironment in solid tumors.Can cancer cells evade the immune system and the relation with immune checkpoint inhibitors?

Cancer cells can indeed evade the immune system through mechanisms like immunoediting, where they silence tumor cell antigen presentation, recruit immunosuppressive cells, and coopt immune checkpoint processes. Immune checkpoint inhibitors target proteins like CTLA-4, PD-1, and PD-L1 to restore the immune system's ability to attack cancer cells and halt their growth. These inhibitors have shown significant antitumor activity by overcoming T-cell regulatory inhibition in cancer patients. However, while checkpoint inhibitors have improved cancer treatment outcomes, they can also lead to side effects like fatigue, skin rashes, and in rare cases, more severe issues such as cardiotoxicity and inflammation.WHAT IS sex differences in cancer incidence IN SHIZOPHRENIA SPECTRUM DISORDER?

The exploration of sex differences in cancer incidence, particularly within the context of schizophrenia spectrum disorder, necessitates a nuanced understanding of the broader landscape of sex disparities in cancer rates and the biological, environmental, and social determinants that may influence these patterns. While the provided contexts do not directly address schizophrenia spectrum disorder, they offer valuable insights into the mechanisms and patterns of sex differences in cancer incidence that could have implications for this specific population. Research has consistently shown that cancer incidence is statistically significantly higher in men than in women for a majority of non-reproductive cancer sites, with disparities exceeding 2-fold for several cancers. This male predominance in cancer incidence is echoed across various studies, indicating that men have a 20% higher chance of developing cancer over their lifetime compared to women. These differences are partly attributed to biological factors, including sex-specific genetic, epigenetic, and hormonal influences that affect cell cycle regulation, immunity, and metabolism. For instance, sex hormones and genetic differences play a role in modulating cancer risk and progression in a sex-specific manner. Environmental and lifestyle factors, alongside social determinants, also significantly contribute to sex disparities in cancer incidence. Studies have highlighted the importance of considering gender as a critical factor in understanding cancer development, pointing to the predominant environmental origin of cancer and its relationship with social determinants. Furthermore, the variability in the male-to-female incidence ratio across different regions suggests the influence of both biological factors and carcinogenic exposure differences. Given the complex interplay of genetic, hormonal, environmental, and social factors in determining cancer risk and incidence, individuals with schizophrenia spectrum disorder may exhibit unique patterns of sex differences in cancer incidence. However, specific research into cancer incidence within this population, taking into account these multifaceted determinants, is necessary to draw definitive conclusions.How does the high mutation rate associated with POLE mutations contribute to the resistance to standard therapeutic approaches?

The high mutation rate linked to POLE mutations contributes to resistance to standard therapies through various mechanisms. POLE mutations, particularly in the exonuclease domain, lead to a significantly increased tumor mutation burden (TMB). These mutations can result in a hypermutated phenotype, impacting immunological markers like TMB and microsatellite instability (MSI). Additionally, POLE mutant tumors may exhibit decreased fidelity of DNA replication, potentially affecting response to treatments. Notably, the presence of POLE mutations, even in microsatellite stable (MSS) colorectal tumors, can still make them effective targets for immunotherapy. Overall, the unique genomic characteristics of POLE mutant tumors, including high TMB and specific co-alterations, suggest a potential role in therapy resistance and the need for further investigation into tailored treatment approaches.Can personalized dietary interventions based on microbiome profiling prevent the onset of dysbiosis-related diseases in high-risk individuals?

Personalized dietary interventions based on microbiome profiling hold promise in preventing dysbiosis-related diseases in high-risk individuals. Studies suggest that understanding the gut microbiota's role can aid in developing preventive strategies. Novel approaches like the Nutrition-Ecotype Mixture of Experts (NEMoE) model can establish associations between microbiota, health states, and diet-specific cohort variability, enhancing predictive performance and identifying microbial signatures of diseases. Furthermore, research indicates that the microbiome plays a crucial role in conditions like gestational diabetes mellitus (GDM), where microbial network analysis can reveal imbalances and aid in individualized diagnosis and therapy strategies. Additionally, manipulating the gut microbiome through dietary interventions has shown potential in improving the efficacy of cancer immunotherapy, highlighting the impact of lifestyle variables on specific microbial populations and host immune responses.